Browse the evidence

Resistance-trained individuals achieve similar quadriceps muscle hypertrophy after eight weeks of resistance training when terminating sets with 1-2 repetitions in reserve (RIR) compared to terminating sets at momentary muscular failure.

If you are experienced with resistance training, you do not need to train to absolute failure on every set to build muscle. Stopping your sets with 1-2 reps left in the tank (RIR) produces the same muscle growth as going to failure over an 8-week period. This approach likely allows you to recover faster and maintain better form, as failure training induces significantly higher acute fatigue and repetition loss.

GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.

If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.

Among GLP-1 receptor agonists, tirzepatide induces the greatest reduction in body mass index (BMI), while orforglipron demonstrates the strongest benefit in lowering systolic blood pressure.

Not all GLP-1 drugs are equal for every health goal. If your primary concern is significant weight loss, tirzepatide shows the greatest BMI reduction in this analysis. If high blood pressure is the main issue, orforglipron showed the strongest blood pressure-lowering effect. Consult your doctor to choose the agent that best targets your specific cardiometabolic risks.

GLP-1 receptor agonist therapies significantly reduce C-reactive protein (CRP) levels, with semaglutide showing the most efficacious reduction compared to other agents.

GLP-1 therapies also help reduce systemic inflammation, as measured by C-reactive protein (CRP). Semaglutide was found to be particularly effective at lowering CRP levels, which may contribute to its cardiovascular benefits.

GLP-1 receptor agonists (specifically liraglutide) significantly reduce body weight and improve cardiometabolic risk factors (BMI, fasting plasma glucose, lipid profile) in obese or overweight individuals with psychotic disorders treated with antipsychotic drugs.

For patients with psychotic disorders on antipsychotics who struggle with obesity, GLP-1 receptor agonists (especially liraglutide) are a proven, effective treatment for weight loss and improving metabolic health. They significantly reduce body weight, BMI, and improve blood sugar and lipid levels without increasing the risk of stopping treatment compared to standard care. Liraglutide appears more effective than exenatide for weight loss in this group.

GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.

GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.

Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.

If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.

Obesity is a heterogeneous condition where distinct subtypes exist based on metabolic and genetic profiles, necessitating personalized treatment strategies rather than uniform BMI-based approaches.

Stop treating all obesity as the same. Your doctor should look beyond your weight to your metabolic health (blood sugar, lipids) and genetics to determine the best treatment for you, which might include specific medications or lifestyle changes tailored to your body's unique biology.

Storing fat subcutaneously (especially in the hips and thighs) is metabolically favorable compared to storing it viscerally or in the liver, reducing the risk of type 2 diabetes and cardiovascular disease despite higher overall body fat.

Focus on maintaining muscle mass and healthy fat distribution rather than just losing weight. If you have a 'pear' shape (fat stored in hips/thighs), you may have a lower risk of diabetes than someone with a 'apple' shape (visceral fat), even if your BMI is high.

Sarcopenia (defined by low handgrip strength and/or low muscle mass) is associated with a significantly higher long-term risk of developing atrial fibrillation (AF) in Caucasian populations, independent of genetic predisposition and lifestyle factors.

Prioritize resistance training and adequate protein intake to maintain muscle mass and strength, especially if you are female or under 65, as these groups showed a stronger link between muscle loss and heart rhythm issues. Regular assessment of handgrip strength and muscle mass can serve as an early warning system for cardiovascular risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.

If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (e.g., liraglutide) induce weight loss primarily by targeting brainstem circuits (specifically the area postrema) rather than mimicking natural gut signals, as natural GLP-1 levels do not regulate body weight.

GLP-1 drugs work by targeting the brainstem to reduce food intake, not by mimicking natural gut signals. This is a distinct mechanism from natural satiety.

Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.

Semaglutide 2.4 mg helps you lose fat mass more than lean body mass, which supports your physical function and walking capacity. This is achieved through once-weekly injections combined with lifestyle changes.

Current GLP-1-based anti-obesity medications (AOMs) achieve profound acute body weight loss (up to 25%) but are associated with significant real-world treatment discontinuation (up to 50%) due to gastrointestinal side effects and lack of lifestyle counseling, necessitating novel formulations with improved tolerability.

While GLP-1 drugs like semaglutide and tirzepatide produce significant weight loss, real-world adherence is a major hurdle due to gastrointestinal side effects. To maximize success, patients should utilize flexible, patient-determined titration schedules rather than fixed rapid escalation, and consider prophylactic anti-emetics if needed, as these strategies improve long-term tolerability and adherence.

Bariatric surgery (RYGB, SG, BPD/DS) is the most effective long-term treatment for severe obesity, achieving 15-30% total weight loss, but carries significant risks of micronutrient deficiencies and lean body mass loss due to anatomical malabsorption.

Bariatric surgery is the most effective long-term weight loss option for severe obesity, but it is not a simple fix. It requires lifelong commitment to high-dose nutritional supplementation and regular medical monitoring to prevent serious deficiencies in iron, B12, and calcium, as well as loss of muscle mass. The procedure works through complex metabolic changes, not just stomach size reduction.

Bariatric surgery significantly increases the risk of bone loss and fractures, particularly in malabsorptive procedures, due to reduced calcium absorption and secondary hyperparathyroidism, which is not fully mitigated by standard calcium and vitamin D supplementation.

If you have bariatric surgery, especially a malabsorptive type like gastric bypass, your risk of bone fractures increases significantly. Standard calcium and vitamin D supplements often fail to prevent this bone loss. You need specialized, long-term bone health monitoring beyond standard care.

Anti-obesity medications (AOMs) such as GLP-1 receptor agonists do not render lifestyle-based treatments obsolete; rather, they act synergistically by addressing physiological barriers to weight loss, allowing behavioral interventions to focus on optimizing body composition and long-term health maintenance.

Do not stop your lifestyle efforts when starting medication. Use the medication to manage hunger and physiological resistance, then redirect that energy into building fitness, muscle mass, and healthy eating habits. The medication handles the biology; you handle the lifestyle optimization for long-term health.

A ketogenic diet tends to cause greater losses in body weight, fat mass, and fat-free mass compared to higher-carbohydrate diets, likely due to differences in calorie and protein intake and fluid shifts rather than the diet itself being inherently superior for fat loss.

If you want to lose fat, a ketogenic diet can help you lose weight, but it is not inherently better than other diets. The greater weight loss seen is likely due to eating fewer calories and losing water weight. Ensure you are consuming enough protein to preserve muscle mass, regardless of the diet you choose.

A ketogenic diet has similar effects on maximal strength or strength gains from resistance training compared to a higher-carbohydrate diet, although a minority of studies show superior effects for non-ketogenic diets.

If your goal is to build strength, you can do so on a ketogenic diet. Studies show similar strength gains compared to high-carbohydrate diets. However, some studies suggest non-ketogenic diets might be slightly superior, so monitor your progress and adjust if needed.

High body mass index (BMI) and visceral adiposity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is critical for kidney health. High BMI and visceral fat directly damage kidneys through increased pressure and hormonal imbalances, leading to chronic kidney disease. While weight loss in advanced kidney disease is complex, preventing obesity is the most effective way to protect your kidneys from long-term damage.

Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.

Obesity increases your risk of developing kidney cancer. Maintaining a healthy weight can help reduce this risk.

Insulin resistance (IR) and the resulting hyperinsulinemia constitute the primary shared pathogenic mechanism linking metabolic syndrome, obesity, and type 2 diabetes (T2DM), driving cardiovascular disease (CVD) risk through prothrombotic effects, endothelial dysfunction, and atherogenic dyslipidemia.

Focus on improving insulin sensitivity through lifestyle changes rather than assuming disease is inevitable due to family history. Managing insulin levels via diet and activity can mitigate the risk of cardiovascular complications associated with metabolic syndrome and obesity.

Metabolomic profiling (metabotyping) reveals that metabolic syndrome, obesity, T2DM, and CVDs share common metabolic signatures and pathways, suggesting that dietary interventions and pharmacologic treatments can target these shared traits.

Understanding that these diseases share metabolic roots allows for integrated treatment strategies, such as dietary changes that address insulin resistance and inflammation, benefiting multiple conditions simultaneously.

Gut microbiota composition determines individual variability in postprandial glycemic responses to standardized meals, enabling prediction of glucose spikes via machine learning models trained on metagenomic data.

Your gut bacteria uniquely determine how your blood sugar reacts to food. This is why one person might spike after a meal while another doesn't. Personalized nutrition strategies based on your microbiome can help manage glucose levels more effectively than generic advice.